[Form 4] Alkermes plc. Insider Trading Activity

Rhea-AI Filing Summary

Alkermes plc (ALKS) reported an insider transaction by its EVP R&D and Chief Medical Officer, Craig C. Hopkinson. On 11/03/2025, he exercised 5,000 employee stock options at $19.34 and, on the same date, sold 9,000 ordinary shares at a weighted average price of $30.3824.

Both the option exercise and the sale were made under a Rule 10b5-1 trading plan adopted on 3/14/2025. The filing notes the sale occurred in multiple transactions at prices ranging from $30.34 to $30.56. Following these transactions, he directly beneficially owned 69,740 ordinary shares. He also reported 40,104 derivative securities (stock options) remaining. The options exercised were fully vested and carry an expiration date of 02/22/2031.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hopkinson Craig C.

(Last) (First) (Middle)

900 WINTER ST.

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Alkermes plc. [ ALKS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP R&D, Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	11/03/2025		M(1)		5,000	A	$19.34	78,740	D
Ordinary Shares	11/03/2025		S(2)		9,000	D	$30.3824(3)	69,740	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$19.34	11/03/2025		M(1)			5,000	(4)	02/22/2031	Ordinary Shares	5,000	$0	40,104	D

Explanation of Responses:

1. This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.

2. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.34 to $30.56. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.

4. These options are fully vested in accordance with their terms.

	/s/ Shantale Greenson, attorney-in-fact for Craig C. Hopkinson	11/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did ALKS disclose on Form 4?

The EVP R&D and CMO exercised 5,000 options at $19.34 and sold 9,000 shares at a weighted average of $30.3824 on 11/03/2025.

Was the ALKS insider transaction under a 10b5-1 plan?

Yes. Both the option exercise and the sale were pursuant to a Rule 10b5-1 plan adopted on 3/14/2025.

How many ALKS shares does the reporting person own after the transactions?

He directly beneficially owned 69,740 ordinary shares after the reported transactions.

What was the price range for the ALKS share sales?

Sales occurred in multiple transactions at prices ranging from $30.34 to $30.56.

How many ALKS options remain held by the insider?

He reported 40,104 derivative securities (stock options) beneficially owned following the transactions.

What is the expiration date of the exercised ALKS options?

The exercised options have an expiration date of 02/22/2031 and were fully vested.